The Food and Drug Administration (FDA) recently approved idelalisib (Zydelig), a new oral inhibitor therapy to treat CLL and SLL. Patients now have another option that may spare them the need for chemotherapy and its associated side effects. A leading researcher in the field from Fred Hutchinson Cancer Research, Dr. John Pagel, shares his perspective on the significance of this new CLL treatment and what it could mean for patients.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…